Loratadine for the Prevention of G-CSF-related Bone Pain

This study tests whether the common antihistamine loratadine (Claritin) can prevent the bone pain that many cancer patients experience when given G-CSF injections (a medication that stimulates white blood cell production after chemotherapy or stem cell transplant). Bone pain from G-CSF can be quite severe, and loratadine is already known to help — this trial aims to confirm its effectiveness. You may be eligible if... - You have been diagnosed with lymphoma or multiple myeloma (confirmed by lab testing) - Your next planned treatment is an autologous stem cell transplant - You are 18 years of age or older - Your performance status is ECOG 0–2 (able to carry out daily activities with mild limitations) - You have a life expectancy of at least 12 weeks - You are able to follow the study schedule and visits You may NOT be eligible if... - You have a known allergy or intolerance to antihistamines - You used antihistamines within two days before the study - You used G-CSF or pegfilgrastim within the past 12 weeks - You have been regularly taking pain relievers within four days before your first G-CSF dose Talk to your doctor to see if this trial is right for you.